The clinical impact of staging bone marrow examination on treatment decisions and prognostic assessment of lymphoma patients.
This study investigates the value of performing a staging bone marrow in patients with diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and classical hodgkin lymphoma (CHL). The results of 3112 staging bone marrow examinations were assessed for impact on prognostic assessment and critical treatment decisions. The detection of marrow involvement altered the disease-specific prognostic index for 4·3% of DLBCL, 6·2% of FL and 0·6% of CHL but marrow involvement in DLBCL was an independent prognostic factor. Knowing the marrow status potentially changed treatment in 92 patients, detection of these patients would have required 854 examinations to be performed.
Epidemiology and Cancer Statistics Group, University of York, York, UK.
Dan
D
Painter
Epidemiology and Cancer Statistics Group, University of York, York, UK.
Alexandra
A
Smith
Haematological Malignancy Diagnostic Service, Leeds Cancer Centre Leeds, Leeds, UK.
Ruth
R
de Tute
Epidemiology and Cancer Statistics Group, University of York, York, UK.
Simon
S
Crouch
Epidemiology and Cancer Statistics Group, University of York, York, UK.
Eve
E
Roman
Haematological Malignancy Diagnostic Service, Leeds Cancer Centre Leeds, Leeds, UK.
Andrew
A
Jack
D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001853:Bone Marrow / Q000473:pathology*; D019468:Disease Management; D005260:Female; D006801:Humans; D008223:Lymphoma / Q000175:diagnosis* / Q000401:mortality / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D011379:Prognosis; D055815:Young Adult
bone marrow examination; flow cytometry; lymphoma; prognosis